Posts Tagged ‘Vantas’
Endo Brochure Silent on Vital Bits—2 Skills for Tonight’s Debate
Read the White Space. Hear the Silence.
MedCity News reports on an Endo Pharmaceuticals brochure under scrutiny by the FDA. The problem was a lack of transparency about the dark side of the therapy—a therapy designed to slow the growth of prostate cancer cells, namely:
- paralysis that may result from the risk of spinal cord compression
- the increased risk of diabetes/heart attack/sudden cardiac death/stroke
In a lively debate in comments section of the Pharmalot blog, the consensus seems to be that the FDA made a good call. Commenters began by speculating this was likely more than just a slight oversight as the Endo communicator skipped regulatory/legal review in a rush to meet a deadline. Then commenters started tracing the language to the Vantas Implant website and began speculating on the rest of their messaging and promotional literature.
The debate amuses me because it is the rare product brochure that is read outside of a sales presentation. And it is even rarer for a brochure to withstand extended exegesis. That the FDA does this regularly earns my respect/awe/fear. Love them or hate them, the FDA’s dogged attention helps medical copywriters and marketers hew to the high road.
The debate also serves as a reminder of the skills needed for watching tonight’s presidential debate. It’s the white space and silence that may be most eloquent. The skill of reading the white space and hearing the silence means the audience must be equipped with the fuller argument. The FDA certainly was. But to read Jill Lepore’s recent New Yorker essay (“The Lie Factory: How politics became a business,” Sept. 24, 2012) is to come away with all the history and reasons as to why the American populace remains a happily uninformed audience. Whitaker and Baxter of Campaigns, Inc. helped set the stage for the current state of our spectatorship:
In tonight’s debate, I’m trying to break free of my usual indolence to hear between the lines (as it were).
###
Image credit: The New Yorker